Samsung Medical Center

A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.

A Pfizer research group, working with Seoul's Samsung Medical Center, has published a study demonstrating a multiplex method for detecting ALK, ROS1, and RET fusions in a single assay.

Using NanoString's nCounter technology, researchers from Pfizer and Seoul National University have developed an ALK test they hope will be as accurate as the gold standard fluorescence in situ hybridization test for identifying patients who could benefit from Pfizer's Xa

NEW YORK (GenomeWeb News) – Agilent Technologies separately announced on Thursday a collaboration with Samsung Medical Center and the creation of a new center for neurometabolomics in South Korea.

The deal also takes Seegene into the personalized medicine space. In addition to tests for detecting cancer, the two companies will develop tests to determine how patients respond to cancer therapies.

Seegene will contribute its DPO and READ PCR technologies; while SMC will provide clinical and disease pathology expertise and the first test sites for the new assays.

Under the terms of the partnership, Samsung will provide samples from Korean patients. Pfizer, in turn, will conduct genomic profiling on the samples and analyze the data in order to link gene signatures to patient outcomes.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.